ArticleResearch square2026
Functionally informed cis and trans proteome-wide association studies prioritize disease-critical genes.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteome-wide association studies (PWAS) typically link genetically predicted protein levels to disease using cis-pQTLs, which can be limited by low cis-heritability for disease-critical genes under negative selection and by tagging due to co-regulation among nearby genes. Trans-pQTLs provide complementary information when large sample sizes are available to detect weak polygenic effects, enabling associations between trans-predicted protein levels and disease. We developed PolyPWAS, a functionally informed, summary statistics-based framework for associating both cis- and trans-predicted protein levels to disease. PolyPWAS integrates 96 functional annotations with proteome-wide pleiotropy to improve protein prediction, while correcting for PCs of predicted protein levels to limit tagging effects. We applied PolyPWAS to 2.8K plasma proteins measured in 34K UKB-PPP participants, analyzing GWAS summary statistics for 88 diseases and complex traits (average
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.